Bruzzoni-Giovanelli, H.; Zouali, H.; Sahbatou, M.; Maneglier, B.; Cayuela, J.-M.; Rebollo, A.; Marin, G.H.; Geromin, D.; Tomczak, C.; Alberdi, A.;
et al. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients. Pharmaceutics 2024, 16, 834.
https://doi.org/10.3390/pharmaceutics16060834
AMA Style
Bruzzoni-Giovanelli H, Zouali H, Sahbatou M, Maneglier B, Cayuela J-M, Rebollo A, Marin GH, Geromin D, Tomczak C, Alberdi A,
et al. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients. Pharmaceutics. 2024; 16(6):834.
https://doi.org/10.3390/pharmaceutics16060834
Chicago/Turabian Style
Bruzzoni-Giovanelli, Heriberto, Habib Zouali, Mourad Sahbatou, Benjamin Maneglier, Jean-Michel Cayuela, Angelita Rebollo, Gustavo H. Marin, Daniela Geromin, Carole Tomczak, Antonio Alberdi,
and et al. 2024. "Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients" Pharmaceutics 16, no. 6: 834.
https://doi.org/10.3390/pharmaceutics16060834
APA Style
Bruzzoni-Giovanelli, H., Zouali, H., Sahbatou, M., Maneglier, B., Cayuela, J.-M., Rebollo, A., Marin, G. H., Geromin, D., Tomczak, C., Alberdi, A., Deleuze, J.-F., & Rousselot, P.
(2024). Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients. Pharmaceutics, 16(6), 834.
https://doi.org/10.3390/pharmaceutics16060834